Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2023-10-30 Earnings Release
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Earnings Release 2023
Earnings Release Classification · 99% confidence The document explicitly states it is the "Q3 2023 report" and contains detailed financial tables comparing Q3 2023 results against Q3 2022, along with year-to-date figures (Jan-Sep). It includes a CEO statement summarizing performance, revenue breakdowns by segment (Haematology, Immunology), adjusted EBITA, EPS, and outlook guidance for the full year 2023. This structure—a comprehensive report covering a period shorter than a full fiscal year (Q3)—is characteristic of an Interim/Quarterly Report. It is not merely an Earnings Release (ER) which typically contains only highlights, nor is it the full Annual Report (10-K). Therefore, the classification is Interim / Quarterly Report (IR). Q3 2023
2023-10-30 English
Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly announces a 'Change in number of shares and votes' following a rights issue. It details the increase in the total number of common shares (from X to 353,756,464) as of a specific date (29 September 2023). This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). Although it is a short announcement, the content is substantive regarding capital structure, making SHA more specific than a general RPA or RNS.
2023-09-29 English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement in Swedish regarding a change in the total number of shares and votes following a rights issue ('företrädesemission'). It explicitly states the new total share count as of September 29, 2023. This type of announcement, detailing changes to the capital structure (share count increase due to a rights issue), fits best under 'Share Issue/Capital Change' (SHA). Although it is a regulatory disclosure, SHA is more specific than the general 'RNS' fallback. The document length is short (1981 chars) and it is a direct announcement, not a link to a larger report, confirming it is the primary filing itself.
2023-09-29 Swedish
Sobi offentliggör slutligt utfall i företrädesemissionen
Capital/Financing Update Classification · 98% confidence The document is a press release from Swedish Orphan Biovitrum AB (Sobi) announcing the final outcome of a rights issue ('företrädesemission'). It details the subscription rate, the amount of capital raised (approximately 6,024 million SEK), and the resulting changes in share capital and the total number of shares. This content directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for 'Capital/Financing Update' (Code: CAP). Although it mentions a prospectus was published, the document itself is the announcement of the final result, not just the announcement of the report's publication (RPA) or a general regulatory filing (RNS).
2023-09-19 Swedish
Sobi publishes the final outcome of the rights issue
Capital/Financing Update Classification · 98% confidence The document is a press release dated September 19, 2023, announcing the 'final outcome of the rights issue' for Swedish Orphan Biovitrum AB (Sobi). It details the subscription rates, the proceeds received (SEK 6,024 million), and the resulting increase in share capital and total number of shares. A rights issue is a specific type of corporate action related to raising capital through existing shareholders. This directly aligns with the definition of 'Capital/Financing Update' (CAP), which covers company fundraising and capital structure changes. It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it concerns a specific financing event.
2023-09-19 English
Sobi offentliggör preliminärt utfall i företrädesemissionen
Capital/Financing Update Classification · 98% confidence The document is a press release from Swedish Orphan Biovitrum AB (Sobi) announcing the preliminary outcome of a rights issue ('företrädesemission'). It details the subscription rates, the expected capital raised (approx. 6,024 million SEK), and changes to the share capital and total number of shares. This content directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it mentions a prospectus, the primary purpose of this specific document is the announcement of the financing result, not just the announcement of the report itself (RPA/RNS).
2023-09-18 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.